药源性肌病的临床表现及致病药物被引量：4

Clinical manifestations and causative drugs of drug-induced myopathy

原文传递

导出

摘要近年,药源性肌病的报道有所增加,本文概要介绍不同类型肌病的临床表现与致病药物及其作用机制,旨在提高临床的诊断能力和安全用药水平。

作者胡晓文陆国椿丁俊杰孙祎

机构地区复旦大学附属肿瘤医院复旦大学附属儿科医院

出处《药物不良反应杂志》 2005年第2期106-108,共3页 Adverse Drug Reactions Journal

关键词药物药源性肌病肌肉损害

参考文献17

1VIctor M, Sieb JP. Myopathies due to drugs, toxins, and nutritional deficiency [A]. In: Myology (2nd ed) [M].Engel AG, Franzinl Armstong C (eds), McGraw-Hill,1997: 1697-1725.
2Ucar M, Mjomdal T, Dahlqvist R. HMG COA reductaseinhibitors and myotoxicity[J]. Drug Safety, 2000, 22(6):441.
3Hargreaves I, Heales S. Statiusandmyopathy[J]. Lancet,2002, 359(2): 711.
4England JD, Walsh JC, Stewart P, et al. Mitochondrial myopathy developing on treatment with the HMG COA reductase inhibitors-simvastatin and pravastatin [J]. Aust N ZJ Med, 1995, (4)25: 374.
5Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis[J]. N Engl J Med, 2002, 346(7):539.
6Argov, Z. Drug-induced myopathies[J]. Curr Opin Neurol,2000, 13(5): 541.
7Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statius implications for therapeuticselection[J].AmJMed, 2001, 111(5): 390.
8Vu D, Murty M, Mcmorran M. Statins: rhabdomyolysis and myopathy[J]. Can Med Assoc J, 2002, 166(1): 85.
9Coquet M, Bannwadh B, Henin D. Myopathies medica menteuses et toxiques[J]. Rev Prat, 2001, 51(3): 278.
10Kolsi R, Bahloul Z, Hachicha J, et al. Dermatopolymyosite induite par la Dpenicillamine aucours de la polyarthrite rhumatoide. Apropos d'un cas et revue de literature[J].Rev Rhum Mal Osteoartic, 1992, 59(5): 341.

1张奇.他汀类药物临床应用注意点[J].临床内科杂志,2006,23(1):12-15. 被引量：8
2杨瑞红,何权瀛.药源性哮喘[J].药物不良反应杂志,2006,8(1):45-49. 被引量：13
3张石革,马国辉.新型直接凝血酶抑制剂——希美加曲上市[J].中国医院用药评价与分析,2006,6(1):8-12. 被引量：10
4王晓翠,张智.服用辛伐他汀并发肌溶解综合征病人的护理[J].护理研究（中旬版）,2007,21(1):175-176. 被引量：4
5刘娟,张程立.他汀类药物相关肌病临床研究进展[J].内科,2007,2(1):107-109. 被引量：7
6Pastermask RC,Smith SCJR,Baireymerz CN,et al.ACC /AHA /NHLB I clinical advisory on the use and safety of statins[J].Circulation,2002,106(8):1024-1028.
7Vasudevan AR, Hasmin YS, Jones PH. Saftey of statins : effect on tousle and the liver[ J]. Cleve Clin J Med ,2005,72:996 - 1001.
8Staffa JA, Charg J, Green L. Cerivastatin and reports of fatel rhabdomyolysis[ J]. N Engl J Med,2002,346(7 ) :539 - 540.
9Pastermask RC,Smith SC Jr, Bairey- merz. CN,et al. ACC/AHA/ NHLBI Clinical advisory On the use and safety of statins[ J]. Circulation,2002,106 : 1024 - 1028.
10Ucar M, Mjomdal T, Dahlqvist R. HMGCOA reduclase - inhibitor and myotoxicity [ J ]. Drug Safety , 2000,22 ( 6 ) :441 - 447.

药物不良反应杂志

2005年第2期

内容加载中请稍等...